03.09.26 -- The Hidden Engineering Behind Successful Upstream Bioprocessing

Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.

This electroporation platform accelerates therapeutic antibody development with scalable, high-efficiency transfection, enabling rapid transient protein expression and IND-enabling studies in weeks.

Discover how N-1 intensification shortens production timelines and improves cell viability by replacing traditional filtration with automated, low-shear separation techniques to achieve higher seeding densities.

To optimize productivity and avoid costly delays for complex proteins, researchers should leverage flexible platforms and experienced CDMOs in cell line development.

Examine how meticulous purification optimization can maximize recovery and impurity removal by leveraging scalable downstream technologies to meet regulatory and process economy requirements.

Continuous bioprocessing is revolutionizing manufacturing. Gain expert insights about cutting-edge innovations in monoclonal antibody production that enable scalable solutions for next-gen therapies.

Scaling up life-saving gene-edited cell therapies means tackling production inefficiencies. Overcoming the time-consuming and risky cell washing step is crucial for clinical and commercial success.

To accommodate the cell expression needs of mAbs, bispecifics, and other advanced multi-specific antibodies, sponsors must leverage a cell line development platform proven to support these modalities.